Comparison of Hospital-at-Home models: a systematic review of reviews

Man Qing Leong 1, Cher Wee Lim 2,3 Yi Feng Lai 2,4,5,6

ABSTRACT

Objectives To provide an overview of the safety and effectiveness of Hospital-at-Home (HaH) according to programme type (early-supported discharge (ESD) vs admission avoidance (AA)), and identify the model with higher evidence for addressing clinical, length of stay (LOS) and cost outcomes.

Methods A systematic review of reviews was conducted by performing a search on PubMed, EMBASE, Cochrane Database of Systematic Reviews, Web of Science and Scopus (January 2005 to June 2020) for English-language systematic reviews evaluating HaH. Data on primary outcomes (mortality, readmissions, costs, LOS), secondary outcomes (patient/caregiver outcomes) and process indicators were extracted. Quality of the reviews was assessed using Assessment of Multiple Systematic Reviews-2. There was no registered protocol.

Results Ten systematic reviews were identified (four high quality, five moderate quality and one low quality). The reviews were classified according to three use cases. ESD reviews generally revealed comparable mortality (RR 0.92–1.03) and readmissions (RR 1.09–1.25) to inpatient care, shorter hospital LOS (MD –6.76 to –4.44 days) and unclear findings for costs. AA reviews observed a trend towards lower mortality (RR 0.77, 95% CI 0.54 to 1.09) and costs, and comparable or lower readmissions (RR 0.68–0.98). Among reviews including both programme types (ESD/AA), chronic obstructive pulmonary disease reviews revealed lower mortality (RR 0.65–0.68) and post-HaH readmissions (RR 0.74–0.76) but unclear findings for resource use.

Conclusion For suitable patients, HaH generally results in similar or improved clinical outcomes compared with inpatient treatment, and warrants greater attention in health systems facing capacity constraints and rising costs. Preliminary comparisons suggest prioritisation of AA models over ESD due to potential benefits in costs and clinical outcomes. Nonetheless, future research should clarify costs of HaH programmes given the current low-quality evidence, as well as address evidence gaps pertaining to caregiver outcomes and adverse events under HaH care.

INTRODUCTION

Healthcare systems around the world are grappling with ageing populations, increasing healthcare needs and expenditures, and shortages of hospital beds and manpower.1 2 Such capacity constraints decrease the efficiency and quality of care delivery, and can lead to delays in elective and emergency treatment,3 increased mortality risk,4 5 lower patient and staff satisfaction, and higher costs for both patients and the health service.6 Chronic morbidity in ageing populations have further driven the rise in healthcare costs.7 These complex challenges pose a threat to the sustainability and quality of care and underscore the need to explore innovative solutions.

An alternative model of care that has been identified as a possible solution is the Hospital-at-Home (HaH) model, in which healthcare professionals deliver hospital-level care in patients’ homes for a limited period of time.8 There are two main types of HaH programmes—early supported discharge (ESD) and admission avoidance (AA). ESD aims to accelerate the discharge of admitted patients, thus, partially substituting hospital care. AA directly admits patients into HaH care. AA generally results in similar or improved clinical outcomes compared with inpatient treatment, and warrants greater attention in health systems facing capacity constraints and rising costs. Preliminary comparisons suggest prioritisation of AA models over ESD due to potential benefits in costs and clinical outcomes. Nonetheless, future research should clarify costs of HaH programmes given the current low-quality evidence, as well as address evidence gaps pertaining to caregiver outcomes and adverse events under HaH care.

Strengths and limitations of this study

- The first systematic review of reviews providing a comprehensive overview of the safety and efficacy of Hospital-at-Home (HaH) according to programme type.
- Compares two major HaH programme types to offer relevant recommendations for health systems facing capacity constraints and rising costs.
- Highlights evidence gaps pertaining to outcomes and process indicators in the current HaH literature.
- Strength of evidence for comparison between HaH models is low due to heterogeneity in implementation and patient groups across studies.
have also been conducted, evidence for some outcomes remains unclear or conflicting, partly due to different approaches between reviews. Greater clarity may be attained by consolidating the reviews. 16

In addition, despite past suggestions that outcomes such as costs and clinical complications vary between ESD and AA models due to differing extents of inpatient care substitution, 17–19 these have not been comprehensively assessed. A 2017 National Institute for Health and Care Excellence guideline 17 presented analyses according to programme type, but the further stratification of results based on level of care precluded any clear conclusions.

Hence, the objectives of this review were to synthesise the evidence for safety and effectiveness of HaH according to programme type, and assess which model had higher evidence for addressing clinical, length of stay (LOS) and cost outcomes. This would guide prioritisation in service planning, particularly for health systems that are grappling with capacity constraints and increasing costs. Process indicators and facilitators and barriers to implementation were also summarised. These are pertinent for potential adopter organisations to evaluate the feasibility of HaH in their respective settings as past studies have pointed to constraints in the HaH model (eg, in terms of patient eligibility due to medical condition severity) 20 and caregiver availability. 21 Moreover, process indicators are valuable in assessing the fidelity of implementation and identifying components that increase the success of HaH implementation. 22

**METHODS**

**Data sources and searches**

A search was performed on 14 January 2020 using PubMed, EMBASE, Cochrane Database of Systematic Reviews, Web of Science and Scopus. Search terms and criteria for inclusion/exclusion were determined a priori by all authors. Test searches were carried out and results were reviewed and refined by two authors before finalising the search strategy. The search was restricted to systematic reviews published after January 2005. While HaH pilot studies have been implemented before that, the care model took time to mature and was largely inconsistently defined prior to a seminal paper in 2005. 3 Hence, reviews after 2005 were considered more representative of the HaH literature. The search strategy employed terms that operationalised ‘review’ and were related to ‘HaH’ (table 1). A prespecified update of the search was performed on 8 June 2020. There was no registered protocol for this study.

**Study selection**

We included systematic reviews of HaH interventions, with HaH defined as the active provision of care by healthcare professionals in patients’ homes for acute and post-acute conditions that otherwise would require hospital inpatient care. While HaH is commonly defined as the provision of acute care at home, we aligned our operational definition with Cochrane reviews which have included trials providing both acute and post-acute services, 23 24 or postacute care alone. 25–27 In addition, care services should only be provided for a time-limited period. 28 29 Systematic reviews including other interventions were eligible if subgroup analyses for HaH were presented. We included reviews which reported at least one of the following: clinical outcomes, resource use or process indicators. Process indicators were defined as measures of the processes involved in achieving programme objectives. 29 English-language systematic reviews of all study designs were eligible.

Reviews of interventions that were delivered in outpatient settings, provided long-term care, or primarily involved patient self-care at home were excluded. We excluded reviews of palliative, obstetric, paediatric and mental health HaH schemes due to differences in these groups’ care needs and objectives from general medicine patients. We excluded reviews that were entirely overlapped by a subsequent update or review of higher quality, as determined using the Assessment of Multiple Systematic Reviews-2 (AMSTAR-2). 30

Literature search and shortlist of the articles were done consistently by one investigator, and shortlisted articles were reviewed by two authors for final inclusion.

**Data extraction and quality assessment**

Review characteristics and relevant outcomes were extracted from the reported findings and tables in the reviews. Primary outcomes of interest were mortality, readmissions, costs and LOS. As the entire treatment duration under HaH is considered inpatient stay, LOS in ESD schemes includes both the stay in the hospital and home. For AA schemes, LOS refers to LOS in the home before discharge from HaH. Secondary outcomes of interest were patient and caregiver satisfaction and caregiver burden. Process indicators (recruitment rates, adverse events) and facilitators and barriers to implementation were also extracted.

Methodological quality of the reviews was assessed using AMSTAR-2, 30 which provides overall ratings (high, moderate, low, critically low) based on weaknesses in critical domains. In line with Cochrane guidelines, 31 methodological quality of the primary studies was determined using the review authors’ original assessments of risk of bias.

**Data synthesis and analysis**

Findings from included reviews were grouped, narratively summarised and compared. Due to heterogeneity between studies, a meta-analysis was not possible.

**Patient involvement**

Patients or the public were not involved in this research. Ethics review was not sought and patient consent was not required.

**RESULTS**

The search returned 7869 potentially relevant references. No relevant papers were identified from the
search update. Ten reviews were eventually included. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow diagram in figure 1 details the article selection process.

**Review characteristics**

The ten reviews (four Cochrane reviews, six non-Cochrane reviews) were published between 2012 and 2017. Cumulatively, there were 100 relevant primary studies, with substantial overlap in studies between reviews (40%). The studies were published between 1976 and 2016, and were mostly from the UK, US, Australia, Italy and Spain.

Some reviews either assessed only ESD or AA interventions, while several reviews included both ESD and AA studies. The reviews were categorised according to three use cases: ESD,\(^2\) AA\(^3\)\(^3\)\(^4\) and ESD/AA.\(^3\)\(^5\)\(^\text{–}\)\(^3\)\(^9\) Characteristics of the reviews are summarised in table 2. Service structure of the HaH programmes in the primary studies varied both within and between reviews. There was

---

**Table 1** Search syntax for database search

<table>
<thead>
<tr>
<th>Database</th>
<th>No</th>
<th>Search</th>
</tr>
</thead>
<tbody>
<tr>
<td>PubMed</td>
<td>#1</td>
<td>Search: ((((((home care services, hospital-based [mesh]) OR (“hospital at home”)) OR (“home hospital”)) OR (“early supported discharge”)(Title/Abstract)) OR (“admission avoidance”)(Title/Abstract)) OR (((home&gt;Title/Abstract)) AND hospital&gt;(Title/Abstract))) AND (((review&gt;(Title/Abstract)OR overview&gt;(Title/Abstract))) OR meta-analysis&gt;(Title/Abstract)) OR meta-review&gt;(Title/Abstract)) OR meta-review&gt;(Title/Abstract)) Filters: English, from 2005 – 2020</td>
</tr>
<tr>
<td>Scopus</td>
<td>#1</td>
<td>(TITLE-ABS-KEY (hospital W/2 home)) OR (ALL (“hospital hospital”)) OR (ALL (“hospital at home”)) OR (TITLE-ABS-KEY (early W/1 support W/1 discharge)) OR (TITLE-ABS-KEY (admission W/1 avoid*)) AND (TITLE-ABS-KEY (overview OR review) OR TITLE-ABS-KEY (meta AND analy*) OR TITLE-ABS-KEY (“meta review”) OR TITLE-ABS-KEY (“review of reviews”)) AND PUBYEAR&gt;2004 AND LIMIT-TO (SUBJAREA, “MEDI”) OR LIMIT-TO (SUBJAREA, “SOCI”) OR LIMIT-TO (SUBJAREA, “HEAL”) AND LIMIT-TO (LANGUAGE, “English”)*</td>
</tr>
<tr>
<td>Cochrane</td>
<td>#1</td>
<td>MeSH descriptor:(Home Care Services, Hospital-Based)explode all trees</td>
</tr>
<tr>
<td></td>
<td>#2</td>
<td>MeSH descriptor: [Home Care Services] explode all trees</td>
</tr>
<tr>
<td></td>
<td>#3</td>
<td>(early NEAR/1 support* NEAR/1 discharge):ab,ti</td>
</tr>
<tr>
<td></td>
<td>#6</td>
<td>(admission NEAR/1 avoid*):ab,ti</td>
</tr>
<tr>
<td></td>
<td>#7</td>
<td>(hospital* NEAR/3 home):ab,ti,kw</td>
</tr>
<tr>
<td></td>
<td>#8</td>
<td>“hospital at home”</td>
</tr>
<tr>
<td></td>
<td>#9</td>
<td>“home hospital”</td>
</tr>
<tr>
<td></td>
<td>#10</td>
<td>#1 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 with Cochrane Library publication date from Jan 2005 to Feb 2020, in Cochrane Reviews</td>
</tr>
<tr>
<td>Web of Science</td>
<td>#1</td>
<td>ts= (hospital* NEAR/3 home)</td>
</tr>
<tr>
<td></td>
<td>#2</td>
<td>ts = “early support discharge”</td>
</tr>
<tr>
<td></td>
<td>#3</td>
<td>ts = “admission avoid”</td>
</tr>
<tr>
<td></td>
<td>#4</td>
<td>ts = “home hospital”</td>
</tr>
<tr>
<td></td>
<td>#5</td>
<td>Tt = “hospital at home”</td>
</tr>
<tr>
<td></td>
<td>#6</td>
<td>#5 OR #4 OR #3 OR #2 OR #1</td>
</tr>
<tr>
<td></td>
<td>#7</td>
<td>ts= (overview OR review OR “meta analy*” OR “meta review” OR “review of reviews”)</td>
</tr>
<tr>
<td></td>
<td>#8</td>
<td>#7 AND #6</td>
</tr>
<tr>
<td></td>
<td>#9</td>
<td>ESCI Timespan=2005–2020</td>
</tr>
<tr>
<td>EMBASE</td>
<td>#1</td>
<td>‘home care’/exp</td>
</tr>
<tr>
<td></td>
<td>#2</td>
<td>‘hospital’/exp</td>
</tr>
<tr>
<td></td>
<td>#3</td>
<td>#1 AND #2</td>
</tr>
<tr>
<td></td>
<td>#4</td>
<td>(hospital* NEAR/3 home):ab,ti,kw</td>
</tr>
<tr>
<td></td>
<td>#5</td>
<td>‘early support* discharge’:ab,ti,kw</td>
</tr>
<tr>
<td></td>
<td>#6</td>
<td>‘admission avoid*’:ab,ti,kw</td>
</tr>
<tr>
<td></td>
<td>#7</td>
<td>#3 OR #4 OR #5 OR #6</td>
</tr>
<tr>
<td></td>
<td>#8</td>
<td>overview:ab,ti OR review:ab,ti OR ‘meta analy*’:ab,ti OR ‘meta review’:ab,ti OR ‘review of reviews’:ab,ti</td>
</tr>
<tr>
<td></td>
<td>#9</td>
<td>#7 AND #8</td>
</tr>
<tr>
<td></td>
<td>#10</td>
<td>#7 AND #8 AND [english]/lim AND(2005–2020)/py</td>
</tr>
</tbody>
</table>
heterogeneity in the team coordinating care (eg, hospital vs community-based), care team composition (eg, nurses, physiotherapists, occupational therapists), programme components (eg, additional elements such as patient and caregiver education), number of home visits, availability of after-hours support and specific medical services provided (eg, home oxygen, intravenous fluids).

Quality of studies
There were four reviews8 28 32 37 of high quality, five33–36 38 of moderate quality and one39 of low quality. Main areas of weakness were the lack of a registered protocol and failure to provide a list of excluded studies (refer to online supplemental table 1) for AMSTAR-2 ratings.

The randomised trials were mostly assessed to be at low risk of bias, while the observational studies were of moderate to high risk of bias.

Outcomes
Detailed findings and summary measures are reported in table 3. As a meta-analysis was not conducted, effect estimates across reviews were summarised descriptively in the main text where feasible to do so (ie, when the same type of effect measure was used across summarised reviews). CIs were included if the effect measure was only reported by one review.

Early-supported discharge
Clinical outcomes
Two reviews28 32 reported that ESD did not significantly affect the mortality rates of elderly patients with a mix of conditions (RR 1.03, 95% CI 0.76 to 1.49; moderate-quality evidence), patients who had a stroke (moderate-quality evidence), and elective surgical patients (MD −3.8% to 0.1%; low-quality evidence).

One review26 revealed a trend towards higher readmissions in ESD schemes for a mix of conditions (RR 1.25, 95% CI 0.98 to 1.58; moderate-quality evidence), whereas readmissions did not differ significantly between ESD and inpatient groups for stroke (RR 1.09, 95% CI 0.71 to 1.66; low-quality evidence) and surgical patients (low-quality evidence). It was unclear if these analyses included readmissions during ESD care.

Resource use and costs
Two reviews28 32 concluded that ESD significantly reduced hospital LOS for all patient groups (MD −6.76 to −4.44 days; moderate-quality evidence), although high heterogeneity in results was observed. Gonçalves-Bradley et al28 observed a significant increase in total LOS (in the hospital and home) across three trials for a mix of conditions (MD 6.43 days, 95% CI 2.84 to 10.03).

Two reviews28 32 found conflicting findings for the effect of ESD on costs (very low-quality evidence). High heterogeneity in cost estimates was also observed due to differences in intervention, cost components and cost measurements across trials. Only one trial factored in community costs; mean hospital cost savings under ESD (at 6 months postrandomisation) were reduced from $A4678 (95% CI $A2676 to $A6680) to $A2013 (95% CI $A669 to $A4696) on factoring in those costs.

Patient and caregiver outcomes
Two reviews28 32 reported that ESD generally led to similar or improved levels of patient and caregiver satisfaction and caregiver strain when compared with inpatient care (low-quality evidence). However, for surgical patients, three out of five trials observed lower caregiver satisfaction under ESD.28

Process indicators
Recruitment rates were low for all patient groups, with a median of 20%–33% of patients meeting eligibility criteria.28 32 Regarding adverse events and clinical complications, one review26 reported a lack of difference between ESD and inpatient groups in three trials for surgical patients, but significantly lower rates of delirium in the ESD group in a trial for a mix of conditions.

Admission avoidance
Clinical outcomes
AA may reduce mortality rates compared with inpatient care. A Cochrane review8 for a mix of conditions reported a trend towards lower mortality under AA schemes at 3 months (RR 0.77, 95% CI 0.54 to 1.09; moderate-quality evidence) and a significant reduction at 6 months (RR 0.77, 95% CI 0.60 to 0.99; moderate-quality evidence). Two other reviews33 34 did not find significant effects on mortality (RR 0.94; 95% CI 0.67 to 1.32),35 but raised the issue of under-powering.
### Table 2  Characteristics of included reviews

<table>
<thead>
<tr>
<th>S/N</th>
<th>Review</th>
<th>Date assessed as up-to-date</th>
<th>Study objectives</th>
<th>Participant characteristics</th>
<th>No of relevant studies*</th>
<th>Study design (no of studies)</th>
<th>Risk of bias of primary studies</th>
<th>AMSTAR-2 rating</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ESD</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>Goncalves-Bradley et al</td>
<td>January 2017</td>
<td>To determine the effectiveness and cost of HaH compared with inpatient hospital care.</td>
<td>Elderly patients with a mix of medical conditions (eg, cardiorespiratory diseases, neurological conditions, fractures), stroke patients, and elective surgical patients (eg, hip and knee replacements)</td>
<td>32</td>
<td>RCT (32)</td>
<td>Majority of the trials were at low risk of bias.</td>
<td>High</td>
</tr>
<tr>
<td>2</td>
<td>Langhorne and Baylan</td>
<td>April 2017</td>
<td>To assess the effect of ESD on hospital LOS, patient and carer outcomes and resource use in comparison with conventional hospital care.</td>
<td>Stroke patients</td>
<td>15</td>
<td>RCT (15)</td>
<td>Trials were generally at low risk of bias, but blinding was impossible.</td>
<td>High</td>
</tr>
<tr>
<td><strong>AA</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>Shepperd et al#8</td>
<td>March 2016</td>
<td>To determine the effectiveness and cost of managing patients with AA HaH compared with inpatient hospital care.</td>
<td>Patients with COPD, stroke, cellulitis, community-acquired pneumonia, fever, neutropenia, dementia, neuromuscular disease and other acute medical conditions</td>
<td>16</td>
<td>RCT (16)</td>
<td>Majority of the studies were at low risk of bias, but unclear risk of bias for selective reporting and performance bias.</td>
<td>High</td>
</tr>
<tr>
<td>5</td>
<td>Qaddoura et al#33</td>
<td>October 2014</td>
<td>To assess the effect of HaH on clinical, patient-centred, and cost outcomes in heart failure in comparison to hospital care.</td>
<td>Patients with heart failure</td>
<td>5</td>
<td>RCT (3), before-and-after study (2)</td>
<td>RCTs were modest in quality. Blinding was not possible for all studies. Several studies had unclear risk of selection bias, high risk of attrition bias, and lack of protocol standardisation. Lack of control for confounders in observational studies.</td>
<td>Moderate</td>
</tr>
<tr>
<td>6</td>
<td>Varney et al#44</td>
<td>2013</td>
<td>To assess the efficacy of AA HaH services that admit patients directly from the ED in comparison to hospital care.</td>
<td>Patients with COPD, cellulitis, pneumonia, heart failure, dementia with acute illness, deep vein thrombosis and other conditions.</td>
<td>16</td>
<td>RCT (9), case–control study (1), observational (3), cost analysis (1)</td>
<td>Majority of the studies were at low risk of bias.</td>
<td>Low</td>
</tr>
<tr>
<td><strong>ESD and AA</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>Caplan#35</td>
<td>February 2012</td>
<td>To assess the effect of HaH services that significantly substitute for in-hospital time (≥7 days or ≥25% of LOS of inpatient controls) on mortality, readmissions, patient and carer satisfaction, and costs.</td>
<td>Medical, surgical and rehabilitation patients &gt;16 years (conditions not specified)</td>
<td>56</td>
<td>RCT (56)</td>
<td>Almost all studies were not blinded.</td>
<td>Low</td>
</tr>
</tbody>
</table>

Continued
<table>
<thead>
<tr>
<th>S/N</th>
<th>Review</th>
<th>Date assessed as up-to-date</th>
<th>Study objectives</th>
<th>Participant characteristics</th>
<th>No of relevant studies*</th>
<th>Study design (no of studies)</th>
<th>Risk of bias of primary studies</th>
<th>AMSTAR-2 rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>8</td>
<td>Sriskandarajah et al[^39]</td>
<td>September 2016</td>
<td>To review observational studies evaluating the safety and effectiveness of HaH and OPAT.</td>
<td>Patients with a mix of conditions (conditions not specified)</td>
<td>6</td>
<td>Observational (6)</td>
<td>Risk of bias ranged from low to high; majority of studies had moderate risk of bias.</td>
<td>Low</td>
</tr>
<tr>
<td>7</td>
<td>Echevarria et al[^36]</td>
<td>November 2014</td>
<td>To assess the safety, efficacy and cost of ESD and AA compared with hospital care for patients with acute exacerbation of COPD</td>
<td>Patients with acute exacerbation of COPD</td>
<td>8</td>
<td>RCT (8)</td>
<td>Low risk of selection bias; high risk of performance bias on subjective outcomes as blinding was not possible; risk of attrition bias in six trials.</td>
<td>Moderate</td>
</tr>
<tr>
<td>8</td>
<td>Jeppesen et al[^37]</td>
<td>October 2010</td>
<td>To evaluate the efficacy of HaH compared with hospital inpatient care in acute exacerbations of COPD.</td>
<td>Patients with acute exacerbation of COPD</td>
<td>8</td>
<td>RCT (8)</td>
<td>Majority of trials had low risk of bias; high risk of bias in one trial due to selective reporting and “other biases” (not described).</td>
<td>High</td>
</tr>
<tr>
<td>9</td>
<td>McCurdy[^38]</td>
<td>August 2010</td>
<td>To compare HaH with inpatient hospital care for patients with acute exacerbations of COPD who present to the ED.</td>
<td>Patients with acute exacerbation of COPD</td>
<td>6</td>
<td>RCT (6)</td>
<td>Majority of the studies had high risk of bias due to lack of allocation concealment, unclear methods for randomisation, unclear binding of assessors, inadequate sample sizes and improper intention-to-treat analyses (withdrawals/dropouts ignored).</td>
<td>Moderate</td>
</tr>
</tbody>
</table>

[Primary studies that did not fulfil eligibility criteria were excluded from this count.]

AA, admission avoidance; AMSTAR-2, Assessment of Multiple Systematic Reviews-2; COPD, chronic obstructive pulmonary disease; ED, emergency department; ESD, early-supported discharge; HaH, hospital-at-home; LOS, length of stay; OPAT, outpatient parenteral antimicrobial therapy; RCT, randomised controlled trial.
<table>
<thead>
<tr>
<th>Review Mortality</th>
<th>Readmissions</th>
<th>LOS</th>
<th>Costs and cost-effectiveness</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ESD</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Goncalves-BRADLEY et al.,2017</td>
<td>Stroke patients: RR 0.92 at 3 to 6 months (95% CI 0.57 to 1.48, p=0.71; 11 trials; moderate-quality evidence). Mix of conditions: RR 1.07 at 3 to 6 months (95% CI 0.76 to 1.49, p=0.71; eight trials; moderate-quality evidence). COPD patients: RR 0.53 (95% CI 0.25 to 1.12, p=0.096; five trials; low-quality evidence). Eletctive surgery patients: little or no difference (range of −3.8% to 0.1%; three trials; low-quality evidence). Stroke patients: RR 1.09 (95% CI 0.71 to 1.66, p=0.70; five trials; low-quality evidence). Mix of conditions: RR 1.25 at 3 months (95% CI 0.98 to 1.58, p=0.069; nine trials; moderate-quality evidence). COPD patients: RR 0.86 (95% CI 0.66 to 1.33, p=0.29; five trials; low-quality evidence). Eletctive surgery patients: little or no difference (five trials; low-quality evidence).</td>
<td>Hospital LOS Stroke patients: MD −6.68 days (95% CI −10.19 to −3.17, p&lt;0.001; four trials; moderate-quality evidence). Median reductions of 8–15 days in six other trials. Mix of conditions: MD −0.36 to −2.2 days (eight trials). Pooled data from four trials: MD −6.76 days (95% CI −10.60 to −2.92, p&lt;0.001; moderate-quality evidence). Orthopaedic surgery patients: MD −4.44 days (95% CI −6.37 to −2.51, p=0.00001; four trials; moderate-quality evidence). Total LOS (with home LOS) Mix of conditions: MD 6.43 days (95% CI 2.84 to 10.03, p&lt;0.001; three trials). Elective surgery patients: MD 2.79 days (95% CI 0.77 to 4.81; two trials).</td>
<td>Initial and total costs were similar, lower or higher than inpatient care across trials (low to very low-quality evidence). Only one trial factored in community costs; mean hospital cost savings (at 6 months post-randomisation) were reduced from $A4678 (95% CI $A2676 to $A6680) to AUD 2013 (95% CI $A669 to $A4696) on factoring in community costs, primarily due to the costs of home-based rehabilitation.</td>
</tr>
<tr>
<td>Langhorne and Baylan,2017</td>
<td>OR 1.04 at 6 months (95% CI 0.77 to 1.40, p=0.81; 16 studies; moderate-quality evidence). Reduced odds of death or dependency in the moderate stroke subgroup (OR 0.77, 95% CI 0.61 to 0.98) than the severe stroke subgroup (OR 1.40, 95% CI 0.83 to 2.38; p=0.04). OR 1.09 at 6 months (95% CI 0.79 to 1.51, p=0.59; six trials; low-quality evidence).</td>
<td>MD −5.5 days (95% CI 2.9 to 8.2, p&lt;0.0001; 16 trials; moderate-quality evidence). Larger reduction for severe stroke subgroup (MD −28 days, 95% CI −17 to −40) than moderate severity subgroup (MD −3 days, 95% CI −1 to −7), p&lt;0.0001.</td>
<td>Total costs ranged from 23% less to 15% greater than inpatient care (seven trials).</td>
</tr>
<tr>
<td><strong>AA</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Shepperd et al.,2016</td>
<td>RR 0.77 at 3 months (95% CI 0.54 to 1.09, p=0.15; five trials; moderate-quality evidence). RR 0.77 at 6 months (95% CI 0.60 to 0.99, p=0.04; six trials; moderate-quality evidence).</td>
<td>RR 0.98 at 3 to 12 months (95% CI 0.77 to 1.23, p=0.84; seven trials; moderate-quality evidence).</td>
<td>Trend towards lower initial and total costs (eight trials). Estimates (bootstrapped MD) of costs varied from $210.90 (95% CI $1025 to $335.47) at 3 months, to $304.72 (95% CI $112.35 to $447.80) per episode. In one trial, cost differences were no longer significant on including the costs of informal care, although HAH might still be cheaper (MD: $2216, 95% CI $4771 to $339).</td>
</tr>
<tr>
<td>Gaddoura et al.,2015</td>
<td>RR 0.94 (95% CI 0.67 to 1.32; p=0.18; three trials). Significant reduction in one observational study (p&lt;0.05). RR 0.68 (95% CI 0.42 to 1.09, p=0.34; two trials); non-significant reduction in one trial; significant reductions in two observational studies (MD −3.80 to −0.70 readmissions per patient). Similar total readmission rates (including readmissions during HaH care) to inpatient care in one study.</td>
<td>RR 0.68 (95% CI 0.42 to 1.09, p=0.34; two trials); non-significant reduction in one trial; significant reductions in two observational studies (MD −3.80 to −0.70 readmissions per patient). Similar total readmission rates (including readmissions during HaH care) to inpatient care in one study.</td>
<td>Significantly longer LOS in three studies (MD 3.0 to 9.1 days)</td>
</tr>
</tbody>
</table>

**Table 3** Detailed primary outcomes in ESD, AA and ESD/AA

- **Mortality**: Mortality was assessed in four studies, with RR 0.92 at 3 to 6 months for stroke patients (95% CI 0.57 to 1.48, p=0.71; 11 trials; moderate-quality evidence). Mix of conditions also showed RR 1.07 at 3 to 6 months (95% CI 0.76 to 1.49, p=0.71; eight trials; moderate-quality evidence). COPD patients showed RR 0.53 (95% CI 0.25 to 1.12, p=0.096; five trials; low-quality evidence). Elective surgery patients demonstrated little or no difference (range of −3.8% to 0.1%; three trials; low-quality evidence).

- **Readmissions**: Stroke patients showed RR 1.09 (95% CI 0.71 to 1.66, p=0.70; five trials; low-quality evidence). Mix of conditions showed RR 1.25 at 3 months (95% CI 0.98 to 1.58, p=0.069; nine trials; moderate-quality evidence). COPD patients showed RR 0.86 (95% CI 0.66 to 1.33, p=0.29; five trials; low-quality evidence). Elective surgery patients demonstrated little or no difference (five trials; low-quality evidence).

- **LOS**: Hospital LOS was evaluated for stroke patients, showing MD −6.68 days (95% CI −10.19 to −3.17, p<0.001; four trials; moderate-quality evidence). Median reductions of 8–15 days in six other trials were also observed. Further, MD −0.36 to −2.2 days (eight trials) and MD −6.76 days (95% CI −10.60 to −2.92, p<0.001; moderate-quality evidence) were noted.

- **Costs and Cost-Effectiveness**: Initial and total costs were similar, lower or higher than inpatient care across trials (low to very low-quality evidence). One trial factored in community costs, with mean hospital cost savings (at 6 months post-randomisation) reduced from $A4678 (95% CI $A2676 to $A6680) to AUD 2013 (95% CI $A669 to $A4696) on factoring in community costs, primarily due to the costs of home-based rehabilitation.
<table>
<thead>
<tr>
<th>Review</th>
<th>Mortality</th>
<th>Readmissions</th>
<th>LOS</th>
<th>Costs and cost-effectiveness</th>
</tr>
</thead>
<tbody>
<tr>
<td>Varney et al, 2014</td>
<td>No significant differences across five trials.</td>
<td>Low rates of unplanned hospital admissions across four observational studies.</td>
<td>Longer LOS across three trials, with significant effects in two trials.</td>
<td>Lower costs across six studies, with significant effects in four studies; statistical significance not reported in the other two studies.</td>
</tr>
</tbody>
</table>

**ESD/AA**

<table>
<thead>
<tr>
<th>Review</th>
<th>Mortality</th>
<th>Readmissions</th>
<th>LOS</th>
<th>Costs and cost-effectiveness</th>
</tr>
</thead>
<tbody>
<tr>
<td>Caplan, 2012</td>
<td>Overall: OR 0.81 (95% CI 0.69 to 0.95, p=0.008; 42 studies) Medical patients: OR 0.79 (95% CI 0.65 to 0.97, p=0.02; 23 studies) Surgical patients: OR 0.78 (95% CI 0.29 to 2.10, p=0.62; five studies) Rehabilitation patients: OR 0.83 (95% CI 0.63 to 1.08, p=0.17; 13 studies)</td>
<td>Overall: OR 0.75 (95% CI 0.59 to 0.95, p=0.02; 41 studies; χ²=73.27, p=0.001) Medical patients: OR 0.76 (95% CI 0.60 to 0.97, p=0.02; 18 studies) Surgical patients: OR 0.66 (95% CI, 0.36 to 1.22, p=0.18; 10 studies) Rehabilitation patients: OR 0.96 (95% CI 0.70 to 1.31, p=0.79; nine studies)</td>
<td>NR</td>
<td>Proportional differences in costs revealed lower costs under HaH. Overall: MD −1567.11 (95% CI −2069.53 to −1064.69, p&lt;0.001; χ²=237.45, p&lt;0.001). Medical patients: MD −1821.69 (95% CI −2591.89 to −1051.49, p&lt;0.001; five studies) Surgical patients: MD −875.89, 95% (CI −3510.96 to 1759.19, p=0.21; two studies) Rehabilitation patients: MD −2704.18 (95% CI −3973.29 to −1435.07, p&lt;0.001; four studies).</td>
</tr>
</tbody>
</table>

| Sriskandarajah et al, 2018    | NR                                                 | Readmission rates during HaH care ranged from 4.2% to 9.7% (5 studies). | NR                                                                 | NR                                                                 |
| Echevarria et al, 2016        | RR 0.66 at 2 to 6 months (95% CI 0.40 to 1.09, p=0.10; seven trials). | Post-HaH discharge readmissions at 2 to 6 months: RR 0.74 (95% CI 0.60 to 0.90, p=0.003; seven trials). Total readmissions: RR 0.84 (95% CI 0.69 to 1.01, p=0.07; seven trials). | NR                                                                 | Lower costs per episode (four trials), but one trial reported higher costs when societal costs (over 3 months) were factored in (HaH: €6,304; Control: €5,395; MD=880; 95% CI −€580 to €2268), and a savings per QALY lost of €31,111. |
| Jeppesen et al, 2012          | RR 0.65 at 2 to 6 months (95% CI 0.40 to 1.04, p=0.07; seven trials; moderate-quality evidence) | Post-HaH discharge readmissions at 1 to 6 months: RR 0.76, (95% CI 0.59 to 0.98, p=0.04; eight trials; moderate-quality evidence). | NR                                                                 | Trend towards reductions in direct costs (three trials; very low-quality evidence). |
| McCurdy, 2012                 | Overall: RR 0.68 at 2 to 6 months (95% CI 0.41 to 1.12, p=0.13; six trials) ESD: RR 0.33 (95% CI 0.13 to 0.85, p=0.02; three trials) AA: RR 0.85 (95% CI 0.45 to 1.62, p=0.63; two studies) | Total readmissions: RR 0.90 (95% CI 0.70 to 1.16, p=0.01; six trials). Readmissions during HaH period accounted for 13% to 50% of total readmissions. | Total LOS was similar to inpatient care in two trials (MD 0.15 to 1.5 days), shorter in one trial (MD −2.9 days), and longer in two trials (mean/median difference 2 to 4.5 days). | NR                                                                 |

All risk ratios (RR), OR and mean differences (MD) are for HaH compared with inpatient care. 
AA, admission avoidance; COPD, chronic obstructive pulmonary disease; ESD, early-supported discharge; HaH, hospital-at-home; LOS, length of stay; NR, not reported.
A review for heart failure observed a trend towards fewer readmissions (post-discharge from HaH) under HaH programmes (RR 0.68, 95% CI 0.42 to 1.09). One study reported total readmissions (inclusive of readmissions during HaH care), which was comparable between AA and inpatient groups. Another review did not find significant differences in total readmissions between groups (RR 0.98, 95% CI 0.77 to 1.23; moderate-quality evidence).

Resource use and costs
Two reviews reported longer LOS (at home) under HaH schemes (MD 3.0–9.1 days). Another review concluded that the effect on LOS was unclear due to high heterogeneity (MD –8.09 to 17 days). However, there was a general trend towards longer LOS.

Three reviews found that HaH reduced costs for the acute episode, with this effect reaching significance in several studies (low-quality evidence). With regards to the mean cost savings per episode, one review reported estimated savings of £304.72 found in one study (95% CI –£447.89 to £1112.35), and another review reported cost savings ranging from £295.97 to £2691. However, Shepperd et al suggested that the cost benefit may be offset by the costs of informal care as one trial revealed that the cost reduction was no longer significant on including informal care costs. Two reviews revealed a trend towards lower total costs (inclusive of follow-up costs) under HaH, although Qaddoura et al concluded that the effect was unclear as few studies included indirect costs.

Patient and caregiver outcomes
One review observed significantly higher levels of patient satisfaction in HaH than inpatient care across most trials (low-quality evidence). Two other reviews also found high levels of satisfaction among HaH patients in observational studies. For caregiver outcomes, Shepperd et al concluded that there was insufficient evidence as two trials revealed conflicting results.

Process indicators
One review reported that recruitment rates for HaH were low but no data was provided. One review concluded that HaH generally did not affect the rate of adverse events. Shepperd et al reported a lack of difference in clinical complications in one trial, and significantly lower rates of bowel and urinary complications and behavioural problems (in dementia patients) under HaH in two trials.

Early-supported discharge and admission avoidance
Clinical outcomes
One review for a mix of conditions reported significantly lower mortality under HaH as compared with inpatient care (OR 0.81, 95% CI 0.69 to 0.95). However, this analysis should be interpreted with caution as several of the included primary studies did not meet the criteria of HaH (eg, nature of care was long-term care or active care was not provided by healthcare professionals). Three reviews for patients with chronic obstructive pulmonary disease (COPD) reported a trend towards lower mortality under HaH (RR 0.65 to 0.68; moderate-quality evidence).

Caplan reported that HaH significantly reduced readmissions compared with inpatient care (OR 0.75, 95% CI 0.59 to 0.95). However, interpretation of this result is constrained as the analysis included four irrelevant studies (psychiatric studies), and this subgroup had the largest effect size among the various specialties. It is also unclear if readmissions during HaH care were included in these analyses. For patients with COPD, two reviews found significant reductions in post-HaH discharge readmissions (RR 0.74–0.76; moderate-quality evidence), while two reviews observed non-significant reductions in total readmissions (RR 0.84–0.90).

Resource use and costs
One review concluded that the effect of HaH on total LOS for patients with COPD could not be determined due to conflicting findings.

Caplan reported that HaH significantly reduced costs compared with inpatient care, although with significant heterogeneity. The cost components of these analyses were unclear. Two reviews for patients with COPD concluded that evidence of cost savings under HaH was of very low quality due to heterogeneity. Echevarria et al reported that one study observed higher costs for HaH than inpatient care when societal costs were included. The study also found that HaH was associated with a savings per quality-adjusted life year (QALY) lost of €31 111.

Patient and caregiver outcomes
One review reported that majority of the trials revealed higher patient and caregiver satisfaction, and lower caregiver burden under HaH. Two reviews reported that the effect of HaH on patient satisfaction for patients with COPD was inconclusive due to limited data (low-quality evidence). One trial observed that HaH did not affect caregiver satisfaction.

Process indicators
COPD-specific reviews reported low recruitment rates, with the percentage of eligible patients ranging from 11% to 39% across trials. A total of 56%–88.5% of eligible patients consented to participation.

McCurdy concluded that HaH did not affect the rate of clinical complications, although there were lower rates of urinary tract infections under HaH in one trial. A review of observational studies observed higher rates of complications in the HaH group than the inpatient group in one study, but the HaH group was also seven times larger. In another study, patients receiving intravenous antibiotics under AA were at lower risk of adverse effects than ESD patients.

Facilitators and barriers
Facilitators to implementation include coordinated and multidisciplinary HaH teams. Barriers to
implementation include physical distance of patients’ homes to the hospital, medical condition stability and level of disability. ESD led to greater reductions in death or dependency and higher cost-effectiveness in one trial when limited to patients with mild or moderate disability. In addition, caregiver availability was an eligibility criteria in one-third to half of the studies across reviews.

**DISCUSSION**

Across ESD, AA and ESD/AA reviews, HaH was generally associated with similar or improved outcomes for mortality and readmissions, shorter hospital LOS and high levels of patient satisfaction compared with inpatient care. While there was a trend towards increased total LOS under both ESD and AA, this is possibly due to the inclusion of postacute care in some schemes. In traditional hospitalisations, patients would likely have been transferred to step-down care facilities (eg, community hospitals, skilled nursing facilities) which are not factored into LOS calculations.

In comparing ESD and AA reviews, ESD has been better studied, but AA may lead to greater benefits in terms of clinical outcomes and costs. AA programmes resulted in either comparable or lower mortality and readmission rates when compared with inpatient care. On the other hand, mortality and readmission rates under ESD were generally similar to inpatient care, but with a concerning trend of higher readmissions in schemes for a mix of conditions. The observed benefit of AA over ESD could have been driven by reductions in iatrogenic events as suggested by past research. However, limited reporting on adverse events precluded clear conclusions. In addition, although the quality of evidence for costs was low across reviews, AA studies revealed consistent cost benefits, in contrast to inconclusive findings under ESD. These observations are aligned with propositions that AA may result in greater cost savings than ESD due to the complete substitution of hospital stay.

Reviews that included both ESD and AA studies were mainly COPD-specific reviews which revealed evidence for lower mortality and readmissions, although with unclear evidence for resource use. Among these reviews, one review conducted subgroup analyses on clinical outcomes by programme type, but the small number of studies (n=5) precluded conclusive interpretation. It should be noted that one review conducted subgroup analyses by the degree of substitution of hospital stay (more than or less than 50%), but the 50% criterion employed did not adequately capture the distinction between ESD and AA. ESD/AA reviews with planned subgroup analyses for programme type should continue to be explored in future research.

Based on the existing evidence, it is recommended to prioritise AA over ESD in HaH implementations due to potential benefits in terms of clinical outcomes, costs and the complete substitution of hospital stay under AA. Nonetheless, it should be cautioned that the strength of evidence for our recommendation is low due to the limitations of our indirect and post hoc comparisons. This is especially so given the heterogeneity in implementation and patient groups across studies. We also acknowledge that it may not always be possible to maintain a clear distinction between ESD and AA in real-life implementations due to operational considerations.

**Recommendations for practice**

The encouraging evidence for clinical outcomes, LOS and costs under HaH, especially the AA model, highlights an opportunity to tackle the bed shortages and spiralling costs faced by health systems. This is particularly pertinent to advanced economies which are grappling with ageing populations and an increasing burden of multimorbidity, complex cases. Moreover, the current COVID-19 pandemic provides greater impetus for HaH implementation. These schemes can be pivotal in decentralising care, facilitating rapid ramp-ups in bed capacity, controlling nosocomial infections.

Notwithstanding the strengths of HaH, the inherent complexity of HaH poses implementation challenges and several factors should be deliberated when planning such schemes. At a broad level, contextual factors for consideration include hospital location and payment structures. Given the low recruitment rates in HaH schemes, HaH may be more practical in urban areas with a sufficient and predictable patient load to allow for greater economies of scale. Second, many countries where HaH has been widely implemented (eg, Australia, UK) have single-payer systems and strong imperatives to keep medical costs low, whereas greater barriers are evident in countries such as the US where payment norms are still predominantly episodic and fee-for-service. Nonetheless, with the shift towards value-based payments and integrated care across health systems, a more conducive environment for HaH may be emerging.

At the programme level, care enablers include the proximity of patients’ homes to the hospital and suitability of home settings. With the policy shift towards bringing care closer to the community, especially in advanced economies, it may be timely to re-examine how future urban planning and housing designs can support models of care such as HaH. Care enablers identified in primary studies which were not included in the current paper deserve mention as well. These include skills training of staff to provide care in HaH schemes and assistive technologies such as telemedicine. Regarding the latter, a recent trial demonstrated the safety and effectiveness of a virtual HaH programme that exclusively utilised telehealth during COVID-19.

Several reviews highlighted that HaH may not be suitable for patients with intensive care needs, or who do not live with caregivers. However, a possible concern with necessitating caregiver availability is the transfer of burden of care from hospitals to family caregivers. In fact, by incorporating appropriate safeguards (eg, panic buttons, fall-detection sensors), caregiver reliance can be reduced while ensuring...
that patients receive quality care. Hence, moving beyond the traditional model of reliance on care providers, HaH can serve as an avenue for patient empowerment by increasing patient involvement in their own care and boosting their confidence in self-management. By extending HaH eligibility to patients without caregivers, more will stand to benefit from HaH schemes as well.

Evidence gaps
The most well-studied diagnostic groups were COPD and stroke, with evidence of positive clinical outcomes for patients with COPD. Past research has indicated that other conditions are also suitable for HaH, such as cellulitis and deep vein thrombosis. However, there was a lack of subgroup analyses or reviews for these conditions, hence the effects of HaH for these groups require further clarification.

It was unclear in multiple reviews if early readmissions during HaH care were factored into analyses for readmissions, hence it was challenging to make comparisons across reviews. Future reviews should clearly report both early and total readmissions. The evidence on costs was of low quality due to heterogeneity across studies, and few studies assessed cost-effectiveness. Future studies could consider full economic evaluations that include all direct and indirect costs (eg, informal care costs) to better guide policy and decision making. Further clarification on caregiver outcomes, especially caregiver burden, is also required given caregivers’ crucial roles in HaH programmes.

Lastly, there was limited reporting on facilitators, barriers and process indicators such as adverse events. Future trials and reviews should report these given that one of the initial objectives of developing the HaH model was to reduce iatrogenic events, and the incidence of iatrogenic events is also a frequently theorised comparison point between ESD and AA.

Limitations
The first limitation is the lack of a registered protocol for this study. In addition, the current research might have missed primary studies that were not included in the systematic reviews, and we also excluded grey literature. However, we attempted to address these limitations by highlighting relevant findings from primary studies and government publications.

Outcomes were mainly limited by small sample sizes and heterogeneous measurement tools in the primary studies. Also, two reviews included primary studies that did not meet the criteria of HaH, hence there were likely inaccuracies in the reported effect estimates.

Lastly, overlaps in primary studies across reviews could have inflated results. This limitation was most pronounced for COPD-specific reviews (90% overlap), but these reviews were included as they provided insight on different outcomes.

CONCLUSION
HaH is largely safe and effective for suitable patients requiring hospital-level care. HaH generally leads to similar or improved clinical outcomes, shorter hospital LOS and high patient satisfaction when compared with inpatient care. HaH particularly warrants greater attention in health systems that are challenged by capacity constraints and rising costs. Moreover, based on preliminary comparisons, AA schemes should be prioritised in further explorations of HaH due to the complete substitution of hospital stay, and possible cost savings which will likely increase with scaled up programmes. However, for both AA and ESD, several outcomes and process indicators still require further clarification, such as caregiver outcomes, cost-effectiveness and clinical complications.

Contributors
As the corresponding author, MQL contributed to the design, data acquisition, analysis and interpretation of the findings, as well as drafting and revising the article. CWL and YFL made a substantial contribution to the conception and design of the study, as well as to interpreting findings, outlining and critical revising of the article. All the authors have provided final approval of the submitted manuscript.

Funding
The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests
None declared.

Patient consent for publication
Not required.

Provenance and peer review
Not commissioned; externally peer reviewed.

Data availability statement
Data sharing not applicable as no datasets generated and/or analysed for this study. All data were obtained from published studies.

Supplemental material
This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs
Man Qing Leong http://orcid.org/0000-0002-6299-1685
Yi Feng Lai http://orcid.org/0000-0002-1318-3032

REFERENCES
12


28 Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017;358:j4008.


